KERX Key Stats
- Keep a Close Watch on Geron, Keryx, and Sangamo Today Fool Dec 6
- Biotech Stock Mailbag: Enteromedics, ARCA Biopharma, Keryx Pharma The Street Dec 6
- Keryx (KERX) Set to Close Near Lows Street Insider Dec 5
- Keryx 'can pretty much forget about' NCE for Zerenex, Feuerstein says theflyonthewall.com Dec 5
- Keryx 'can pretty much forget about' NCE for Zerenex, Feuerstein þsays theflyonthewall.com Dec 5
- Keryx Zerenex still well-positioned to gain market share, says JMP Securities theflyonthewall.com Dec 2
- Zerenex- The New Spark For Keryx? Seeking Alpha Nov 25
- Here's What This Big-Time Hedge Fund Has Bought Lately Fool Nov 19
- Why Doctors, Dialysis Providers And Investors Are Excited About Zerenex Seeking Alpha Nov 11
- This Week in Biotech Fool Nov 9
KERX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Keryx Biopharmaceuticals is up 342.7% over the last year vs S&P 500 Total Return up 30.43%, Amarin down 85.19%, and Endo Health Solutions up 135.6%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for KERX
Pro Report PDF for KERX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download KERX Pro Report PDF
Pro Strategies Featuring KERX
Did Keryx Biopharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company engaged in the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease.